EIF3D was identified to enhance the sensitivity of cancer cells to some chemotherapeutics, such as hydroxyurea, chelerythrine, and vorinostat, while LARP1 weakened the sensitivity of denileukin diftitox ontak. The gene discussed is EIF3D; the disease is cancer.